Jump Financial LLC Sells 85,354 Shares of REGENXBIO Inc. $RGNX

Key Points

• Jump Financial LLC reduced its stake in REGENXBIO Inc. by 44.3%, owning approximately 0.21% of the company after selling 85,354 shares.
• REGENXBIO reported an EPS of -$1.38 for the last quarter, missing estimates and showing a significant negative net margin of 112.70%.
• Analysts have mixed opinions on REGENXBIO, with ratings ranging from a "strong sell" to "buy," and a current consensus target price of $28.38.

Jump Financial LLC cut its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 44.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,354 shares of the biotechnology company's stock after selling 85,354 shares during the quarter. Jump Financial LLC owned 0.21% of REGENXBIO worth $768,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Millennium Management LLC increased its holdings in shares of REGENXBIO by 406.3% in the 4th quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock valued at $10,222,000 after purchasing an additional 1,061,187 shares during the period. Vanguard Group Inc. increased its holdings in shares of REGENXBIO by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock valued at $24,832,000 after purchasing an additional 487,036 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $2,793,000. Two Sigma Investments LP increased its holdings in shares of REGENXBIO by 209.2% in the 4th quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company's stock valued at $3,010,000 after purchasing an additional 263,495 shares during the period. Finally, Jane Street Group LLC increased its holdings in REGENXBIO by 325.3% in the fourth quarter. Jane Street Group LLC now owns 164,911 shares of the biotechnology company's stock worth $1,275,000 after buying an additional 126,135 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a report on Saturday, August 9th. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a report on Friday, August 8th. Chardan Capital restated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Friday, August 8th. Royal Bank Of Canada dropped their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a research report on Tuesday, August 19th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $28.38.

REGENXBIO Stock Performance

Shares of RGNX traded up $0.41 during mid-day trading on Friday, hitting $9.83. The company's stock had a trading volume of 163,423 shares, compared to its average volume of 943,869. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $13.48. The firm has a market capitalization of $496.36 million, a PE ratio of -2.87 and a beta of 1.17. The stock's 50-day moving average is $8.63 and its two-hundred day moving average is $8.16.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The firm had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. Analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.